Stivarga regorafenib: Phase IIIb data

The open-label, international Phase IIIb CONSIGN trial in 2,872 mCRC patients who progressed after standard therapy showed that once-daily 160 mg oral Stivarga for the first 3 weeks of a 4-week cycle ...